RLMD

RELMADA THERAPEUTICS, INC. RLMD

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$693.67M total
Jupiter Topco LLC
$77.32M--
BlackRock, Inc.
$51.39M+475.9%
Squadron Capital Management LLC
$50.86M-13.3%
VR Adviser, LLC
$47.36M+41.3%
Spruce Street Capital LP
$44.23M+2.1%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$32.96M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$30.86M+45.0%
Jones Hill Capital LP
$25.29M+966.4%
ORBIMED ADVISORS LLC
$25.13M-23.0%
STATE STREET CORP
$17.42M+605.1%
GEODE CAPITAL MANAGEMENT, LLC
$17.25M+193.7%
MILLENNIUM MANAGEMENT LLC
$16.34M-39.6%
MARSHALL WACE, LLP
$15.55M-49.9%
Ikarian Capital, LLC
$14.87M-20.1%
DRIEHAUS CAPITAL MANAGEMENT LLC
$14.75M0.0%
AMERIPRISE FINANCIAL INC
$13.41M+263.4%
EVENTIDE ASSET MANAGEMENT, LLC
$12.86M+120.7%
BALYASNY ASSET MANAGEMENT L.P.
$10.52M+502.4%
StemPoint Capital LP
$10.10M+144.4%
Commodore Capital LP
$9.86M+124.8%
Polar Capital Holdings Plc
$9.28M-5.2%
CITADEL ADVISORS LLC
$7.35MNew
Sio Capital Management, LLC
$6.94M+4.0%
Opaleye Management Inc.
$6.47M0.0%
VANGUARD PORTFOLIO MANAGEMENT LLC
$6.22MNew
See all 126 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/RLMD

Earnings Per Share

13fpro.ai/company/RLMD

Loading ratio trend…

RLMD key financials by period

Reported revenue, net income and operating margin by fiscal year, from RELMADA THERAPEUTICS, INC.'s annual filings on SEC EDGAR.

RELMADA THERAPEUTICS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2013$5.1K$-45.0K—
FY 2012$7.9K$-12.1K-151.8%
Source: RLMD filings on SEC EDGAR →

RLMD insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in RLMD

2 transactions in RLMD reported by 1 member of Congress under the STOCK Act, most recent trade Dec 12, 2022. Reported transactions, not recommendations.

All Congress stock trades →

About RELMADA THERAPEUTICS, INC. (RLMD): stock profile, AI score and financials

RELMADA THERAPEUTICS, INC. (RLMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. RLMD is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of RLMD by reported 13-F value include Jupiter Topco, BlackRock, Squadron Capital Management, based on the most recent SEC filings. RLMD trades on the Nasdaq exchange and files with the SEC under CIK 1553643. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RLMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RELMADA THERAPEUTICS, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1553643 →